News + Resources
Pro-Innovation M&A Allows Life Sciences Innovators to Weather the Significant Costs of R&D
Life sciences companies of all sizes face extended time and cost pressures as they work to bring new medicines to patients, as the average cost of research and development (R&D) can exceed $2.8 billion, and it can take more than 10-15 years to bring a new therapy...
Backgrounder: The Role of M&A Policy in the Life Sciences and its Impacts on Innovation
Mergers and acquisitions allow life sciences companies of all sizes to bring together the resources, investment and expertise needed to develop and deliver new treatments and cures for patients. Unfortunately, the latest merger guidelines and proposed premerger notification requirements issued by the Federal Trade Commission (FTC) and Department of Justice (DOJ) reflect a misguided approach that will prevent and deter pro-innovation M&A and disrupt our world-class American life sciences ecosystem.
Changes to HSR Premerger Rules Would Add Unnecessary Financial and Operational Barriers to Pro-Innovation M&A
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements...
An Interview with AZBio President and CEO on Life Sciences M&A in Arizona
PULSE had a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. Joan, who has led AZBio since 2011, has a vested interest in making Arizona a place where...
New NAM Report Finds Biopharmaceutical R&D Investment Crucial for Patients, the Economy
Thousands of life sciences companies from across the U.S. compete every day to bring the next generation of treatments and cures to market. Within this ecosystem, pharmaceutical manufacturers play a key role in developing new therapies and cures. By mobilizing their...